摘要
目的评价复方血栓通与卵磷脂络合碘联合治疗初诊为中心性浆液性脉络膜视网膜病变患者的疗效与安全性。方法将初诊为中心性浆液性脉络膜视网膜病变256例患者分为对照组A(84例94眼)、对照组B(79例88眼)与治疗组(93例102眼),对照组A给予复方血栓通1.5 g,对照组B给予卵磷脂络合碘1.5mg,治疗组给予复方血栓通1.5 g与卵磷脂络合碘1.5 mg,均饭后服用,每日3次。用光学相干断层扫描技术、眼底照像及视网膜血管荧光造影、标准对数视力表等随访复诊,记录患者用药疗效与安全性。结果治疗组比对照组A、B能明显缩短病程,12周后总有效率和总显效率与对照组比较,差异有统计学意义(P<0.05)。对照组B和治疗组分别有7,9例患者出现胃肠道不良反应。结论复方血栓通与卵磷脂络合碘联用治疗初诊为中心性浆液性脉络膜视网膜病变能促进渗漏吸收和改善脉络膜微循环、缩短病程、改善视力、降低复发率,疗效明确。
Objective To evaluate the effect and safety of Fufang Xueshuantong combined with lecithinbound iodine on the treatment of newly diagnosed central serous chorioretinopathy（ CSC）. Methods Two hundred fiftysix patients with newly diagnosed CSC were divided into control group（ A） with ninetyfour eyes in eightyfour patients, control group（ B） with eightyeight eyes in seventynine patients and therapeutic group with one hundred and two eyes in ninetythree patients. Control group（ A） and control group（ B） were respectively treated by Fufang Xueshuantong and lecithinbound iodine. Both of two drugs were used to treat patients in therapeutic group. Each case was requested to return visit and inspected with optical coherence tomography（ OCT）,fundus fluorescein angiography,standard logarithmic visual acuity chart,etc. The clinical effect of drugs in the three groups were recorded and analyzed comparatively. Results The course of the therapeutic group was significantly shorter than the control group（ A / B）. There were significant differences in total effective rate and total obvious effective rate after twelve weeks of treatment between the therapeutic group and the control group（ A / B）（ P 0. 05）. Seven patients in control group（ B） and nine patients in therapeutic group respectively had gastrointestinal reaction. Conclusion Fufang Xueshuantong combined with lecithinbound iodine has the effect of improving absorption of leakage and microcirculation of choroid,which can shorten the course, promote the recovery of visual function and reduce the relapse rate on the treatment of newly diagnosed CSC.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2013年第12期893-896,共4页
The Chinese Journal of Clinical Pharmacology
基金
常州四药临床药学科研基金资助项目(CY20119023)
